COHR · Investment summary · as of 12 August 2026
Priced slightly ahead of what the business has demonstrated
Business type: Cyclical · cyclical or commodity-sensitive
The operating path required by today's price is not achievable on the evidence.
At $355.64, COHR requires a 76% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 7%.
The conditions that would settle the disagreement are dated to November 2026.
The value rests on an exit multiple of 7.5x, a terminal operating margin of 20% and a 13.8% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: The indium-phosphide capacity build inverts from a moat into a stranded asset.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Filed FY GAAP operating margin over ten years: 15.3% (FY2017) -> 1.7% (FY2020) -> 13.3% (FY2022) -> -0.7% (FY2023) -> 2.0% (FY2024) -> 5.0% (FY2025) -> 12.6% (FY2026). A 14.0pp band disqualifies State A. |
| What do we forecast? | Revenue growth of 7% demonstrated; a terminal operating margin of 20%; an exit multiple of 7.5x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On terminal margin, the difference between what the price requires and what the business has demonstrated is -14.2 percentage points. |
| What is it worth? | Not determined — It is struck at this name's next touch. |
| Why now? | The first dated test of the thesis falls on 4 November 2026. |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 4 November 2026 | Reported quarterly revenue | Q1 FY2027 revenue at or above $2,200m | Q1 FY2027 revenue below $2,200m |
| Q1 FY2027 and Q2 FY2027 | Non-GAAP gross margin from the quarterly reconciliation… | Non-GAAP gross margin at or above 39.5% for two consecutive quarters | Non-GAAP gross margin below 39.5% for two consecutive quarters |
| any 10-Q from Q1 FY2027 | Same-quarter DIO from the balance sheet and COGS, and segment revenue… | Days inventory outstanding above 200 days on a same-quarter basis while Datacenter & Communications YoY growth falls at… | Days inventory outstanding above 200 days on a same-quarter basis while Datacenter & Communications YoY growth falls… |
| tested at each 10-Q through FY2027; satisfied only if still negative at the FY2027 10-K | CFO less capex, TTM, from the cash-flow statement | Neither leg of the condition opposite is met at this date | Free cash flow does not return to positive on a trailing-twelve-month basis by the end of FY2027 |
The indium-phosphide capacity build inverts from a moat into a stranded asset. COHR is supply-constrained today, which is why FY2026 capex ran $1,102.9m (2.50x FY2025) and inventory rose 79.5% to $2,581.0m. The bear case is that the constraint resolves industry-wide — external InP capacity arrives, silicon photonics displaces EML at 1.6T, or co-packaged optics collapses pluggable transceiver volumes faster than COHR's own CPO line ramps. COHR then holds $2.6bn of inventory and a heavily capitalised 6-inch InP fab against falling ASPs, with 22% of revenue in two unnamed counterparties who have every incentive to dual-source, and with the Industrial segment (26% of revenue) already declining 10.3%.
Estimated probability 20%, against the 12% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
EV/NTM consensus revenue above 8.5x on the fully diluted count (7.57x today, already the 100th percentile of the name's own history). The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | The indium-phosphide capacity build inverts from a moat into a stranded asset. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -14.2 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: the indium-phosphide capacity build inverts from a moat into a stranded asset. The next evidence that should change the portfolio decision is the test dated 4 November 2026, or a daily close below $266.73, which forces an immediate review.